Nurix Therapeutics (NRIX) USPTO patents

Utility

Bifunctional Compounds for Grading BTK Via Ubiquitin Proteosome Pathway

26 Jan 23

Daniel W. ROBBINS, Ge PENG, Jeffrey MIHALIC, Arthur T. SANDS

Filed: 8 Nov 19

Utility

Bifunctional Compounds for Degrading BTK Via Ubiquitin Proteosome Pathway

26 Jan 23

The present invention relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway.

Daniel W. ROBBINS, Arthur T. SANDS, Joel MCINTOSH, Jeffrey MIHALIC, Jeffrey WU, Daisuke KATO, Dahlia WEISS, Ge PENG

Filed: 28 Jul 22

Utility

Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof

20 Dec 22

Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed.

Arthur T. Sands, Neil F. Bence, Christoph W. Zapf, Frederick Cohen, Chenbo Wang, Thomas Cummins, Hiroko Tanaka, Hunter Shunatona, Mario Cardozo, Dahlia Weiss, Jennifa Gosling

Filed: 15 May 20

Utility

Urea, Amide, and Substituted Heteroaryl Compounds for CBL-B Inhibition

8 Dec 22

Arthur T. SANDS, Neil F. BENCE, Christoph W. ZAPF, Frederick COHEN, Chenbo WANG, Thomas CUMMINS, Hiroko TANAKA, Morgan LAWRENZ, Mario CARDOZO, Dahlia WEISS, Jennifa GOSLING

Filed: 27 Jul 20

Utility

3-SUBSTITUTED Piperidine Compounds for CBL-B Inhibition, and Use Thereof

1 Dec 22

Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed.

Arthur T. SANDS, Neil F. BENCE, Christoph W. ZAPF, Frederick COHEN, Chenbo WANG, Thomas CUMMINS, Hiroko TANAKA, Hunter SHUNATONA, Mario CARDOZO, Dahlia WEISS, Jennifa GOSLING

Filed: 13 Jul 22

Utility

Combination Therapies with CBL-B Inhibitor Compounds

27 Oct 22

The present disclosure relates to combination therapies with Cbl-b inhibitor compounds, and compositions and kits comprising combinations with the Cbl-b compounds.

Cristiana GUIDUCCI, Marilena GALLOTTA

Filed: 8 Apr 22

Utility

Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway

25 Oct 22

The present invention relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway.

Daniel W. Robbins, Arthur T. Sands, Joel McIntosh, Jeffrey Mihalic, Jeffrey Wu, Daisuke Kato, Dahlia Weiss, Ge Peng

Filed: 14 Oct 19

Utility

Inhibitors of CBL-B and Methods of Use Thereof

13 Oct 22

Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed.

Paul A. BARSANTI, Neil F. BENCE, Jennifa GOSLING, Anjanabha SAHA, Asad M TAHERBHOY, Christoph W. ZAPF, Kathleen BOYLE, Mario CARDOZO, Jeffrey MIHALIC, Morgan LAWRENZ, Mark GALLOP, Jilliane BRUFFEY, Thomas CUMMINS, Daniel ROBBINS, Hiroko TANAKA, Chenbo WANG, Frederick COHEN, Wylie PALMER, Arthur T. SANDS, Hunter SHUNATONA

Filed: 25 Jan 19

Utility

3-substituted piperidine compounds for Cbl-b inhibition, and use thereof

11 Oct 22

Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed.

Arthur T. Sands, Neil F. Bence, Christoph W. Zapf, Frederick Cohen, Chenbo Wang, Thomas Cummins, Hiroko Tanaka, Hunter Shunatona, Mario Cardozo, Dahlia Weiss, Jennifa Gosling

Filed: 9 Apr 20

Utility

Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof

2 Aug 22

Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed.

Arthur T. Sands, Neil F. Bence, Christoph W. Zapf, Frederick Cohen, Chenbo Wang, Thomas Cummins, Hiroko Tanaka, Hunter Shunatona, Mario Cardozo, Dahlia Weiss, Jennifa Gosling

Filed: 26 Jun 20

Utility

Bifunctional Compounds for Degrading BTK Via Ubiquitin Proteosome Pathway

12 May 22

The present invention relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway.

Diasuke KATO, Zef KNOST, Jeffrey MIHALIC, Daniel W. ROBBINS, Arthur T. SANDS

Filed: 4 Feb 20

Utility

Bifunctional Degraders of Hematopoietic Progenitor Kinase and Therapeutic Uses Thereof

18 Nov 21

The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteosome pathway, and method for treating diseases modulated by HPK1.

Hunter P. Shunatona, Galen Paul Shearn-Nance, Scott A. Mitchell, John Buell

Filed: 5 May 21

Utility

Bifunctional Compounds for Degrading BTK Via Ubiquitin Proteosome Pathway

1 Jul 21

This disclosure relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway.

Aileen KELLY, Arthur T. SANDS

Filed: 3 Dec 20

Utility

CBL Inhibitors and Compositions for Expansion of Immune Cells

25 Mar 21

Methods and compositions using novel Cbl inhibitors enhancing expansion of immune cells to increase the efficacy of cell-based immunotherapeutics are disclosed.

Jennifa GOSLING, Arthur T. SANDS, Sarah Anne WHELAN, Michael LOTZE

Filed: 23 Sep 20

Utility

CBL Inhibitors and Compositions for Use In Adoptive Cell Therapy

25 Mar 21

Methods and compositions using novel Cbl inhibitors for supporting engraftment of immune cells to increase the efficacy of cell-based immunotherapeutics are disclosed.

Jennifa GOSLING, Arthur SANDS, Sarah Anne WHELAN, Cristiana Guiducci

Filed: 23 Sep 20

Utility

Substituted Benzyl-triazole Compounds for CBL-B Inhibition, and Further Uses Thereof

25 Feb 21

Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed.

Arthur T. SANDS, Neil F. BENCE, Christoph W. ZAPF, Frederick COHEN, Chenbo WANG, Thomas CUMMINS, Hiroko TANAKA, Hunter SHUNATONA, Mario CARDOZO, Dahlia WEISS, Jennifa GOSLING

Filed: 26 Jun 20

Utility

Cyano Cyclobutyl Compounds for CBL-B Inhibition and Uses Thereof

25 Feb 21

Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed.

Arthur T. SANDS, Neil F. BENCE, Christoph W. ZAPF, Frederick COHEN, Chenbo WANG, Thomas CUMMINS, Hiroko TANAKA, Hunter SHUNATONA, Mario CARDOZO, Dahlia WEISS, Jennifa GOSLING

Filed: 15 May 20

Utility

3-SUBSTITUTED Piperidine Compounds for CBL-B Inhibition, and Use of a CBL-B Inhibitor In Combination with a Cancer Vaccine And/or Oncolytic Virus

14 Oct 20

Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed.

Arthur T. Sands, Neil F. Bence, Christoph W. Zapf, Frederick Cohen, Chenbo Wang, Thomas Cummins, Hiroko Tanaka, Hunter Shunatona, Mario Cardozo, Dahlia Weiss

Filed: 8 Apr 20